Physician profile
Anshuman Das
NPI 1518255124
$19,247.23
in general payments reported to CMS, 2019-2025
24 companies · $7,241 in 2025
The $7,241 reported for 2025 was more than what 86% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,548 · 2020: $679 · 2021: $1,219 · 2022: $2,872 · 2023: $3,643 · 2024: $2,045 · 2025: $7,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,946 · Travel and Lodging: $5,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,946.02 |
| Travel and Lodging | $5,983.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $5,732.97 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Boston Scientific Corporation | $4,036.39 | 2019-2025 | General - Vascular Access, Watchman Access System, Stingray |
| Abbott Laboratories | $3,680.74 | 2019-2025 | Mitraclip, Cardiomems, Amplatzer Torqvue 45 X 45 |
| Medtronic, INC. | $2,879.11 | 2022-2025 | Corevalve Evolut R, Symplicity G3, Venaseal |
| Abiomed | $826.14 | 2019-2025 | Impella |
| Shockwave Medical, INC | $542.77 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $303.21 | 2019-2025 | |
| Amgen INC. | $289.86 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.93 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $178.15 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $122.32 | 2019-2020 | |
| Teleflex LLC | $96.66 | 2022-2025 | Guideliner |
| Cardiovascular Systems INC. | $72.90 | 2019 | |
| Medical Device Business Services, INC. | $58.81 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.30 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44.10 | 2021-2022 | |
| Angiodynamics, INC. | $38.73 | 2023 | Alphavac |
| Regeneron Healthcare Solutions, INC. | $20.24 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.17 | 2023 | Onpattro |
| Bard Peripheral Vascular, INC. | $17.51 | 2022 | |
| W. L. Gore & Associates, INC. | $13.71 | 2022 | |
| Gilead Sciences, INC. | $13.59 | 2019 | |
| Amryt Pharma Holdings Ltd | $11.97 | 2021 | |
| Esperion Therapeutics, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anshuman Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.